Navigation Links
Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
Date:9/26/2007

CAMBRIDGE, Mass., and BERLIN, Sept. 26 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) and Bayer Schering Pharma AG, Germany today announced that the first patient has been treated in the first of two planned Phase 3 trials examining the safety and efficacy of alemtuzumab for the treatment of multiple sclerosis (MS).

The CARE-MS I trial (Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis), a randomized, rater-blinded study, will compare alemtuzumab to Rebif(R) (interferon beta-1a) in patients with relapsing- remitting multiple sclerosis (MS). Alemtuzumab will be given in two annual cycles; Rebif will be administered three times per week. The CARE-MS I study will include patients who have been diagnosed with relapsing-remitting MS but who have not yet begun treatment with any MS drug. CARE-MS II is scheduled to begin soon and will enroll patients who have continued to experience relapse episodes while on currently available disease-modifying therapies.

Initiation of this Phase 3 program follows the successful completion of the initial treatment period in the Phase 2 trial. Interim results from the Phase 2 trial indicated that alemtuzumab-treated patients experienced a statistically significant reduction compared with Rebif-treated patients in the risk for sustained accumulation of disability and the risk for relapse for 24 months. Results of the primary outcomes from this trial at 36 months are expected to be presented on Oct. 14 by Professor Alastair Compston during the Charcot Award lecture at the annual meeting of the European Committee for Treatment and Research in Multiple Sclerosis, in Prague.

The CARE-MS I study will enroll up to 525 patients at approximately 60 med
'/>"/>

SOURCE Genzyme Corporation; Bayer Schering Pharma AG
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
2. Genzyme Announces Results of Clinical Trial of Hylastan
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
5. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
6. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
7. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
8. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
9. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
10. Sygnis Pharma AG announces date for presentation of clinical results
11. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)...   Easy Breathe , the fastest growing online sleep ... " - has received more than 4.5 million unique page views ... thrilled that so many people are finding our blog and reading ... "We,re committed to making sleep apnea more widely known and hope ... sleep apnea news , troubleshooting advice , and ...
(Date:8/20/2014)... NEW YORK , Aug. 20, 2014 /PRNewswire/ ... new market research report is available in its ... Electronic Medical Records http://www.reportlinker.com/p0833392/EMR-2014-The-Market-for-Electronic-Medical-Records.html ... fast-changing market for electronic medical records (EMR) for ... a comprehensive report of our findings. Our report ...
(Date:8/20/2014)... 20, 2014 Phase I Trial ... US  KalVista Pharmaceuticals ("KalVista"), an ophthalmology company ... announces that it has begun a Phase I, First ... KVD001, for the treatment of DME. The study,s Principal ... Eye Institute, Joslin Diabetes Center; Harvard Medical School Department ...
Breaking Medicine Technology:Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 2Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 3Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 4EMR 2014: The Market for Electronic Medical Records 2EMR 2014: The Market for Electronic Medical Records 3EMR 2014: The Market for Electronic Medical Records 4EMR 2014: The Market for Electronic Medical Records 5EMR 2014: The Market for Electronic Medical Records 6EMR 2014: The Market for Electronic Medical Records 7EMR 2014: The Market for Electronic Medical Records 8KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4
... Galleon Pharmaceuticals, a leader in the pharmaceutical treatment of ... has elected Thomas J. Dietz, Ph.D., as the company,s ... Holdings, LLC, a diversified financial-holdings and services company.   ... then CEO and a director of Pacific Growth Equities, ...
... Reportlinker.com announces that a new market ... Medical Imaging Markets: Contrast ... The application and versatility of ... in significance as the population ages and ...
Cached Medicine Technology:Thomas Dietz, Ph.D., Elected Chairman of Galleon Pharmaceuticals 2Medical Imaging Markets: Contrast Agents 2Medical Imaging Markets: Contrast Agents 3Medical Imaging Markets: Contrast Agents 4Medical Imaging Markets: Contrast Agents 5Medical Imaging Markets: Contrast Agents 6
(Date:8/20/2014)... The Board of Directors of top ... is pleased to announce the expansion of its ... and the surrounding region. In support of this ... AIA has relocated to the firm’s office in Shanghai, ... and design and to better support regional clients. ...
(Date:8/20/2014)... the most persistent and deadliest infectious diseases in the ... , Scientists who study tuberculosis have long debated its ... humans in Africa to seals and sea lions that ... to Native people there before Europeans landed on the ... as a Source of New World Human Tuberculosis," was ...
(Date:8/20/2014)... through fast-moving waters may be at risk, suggests new ... salmon encounter turbulent, fast-moving water such as rapids ... upstream using a behaviour known as "burst swimming" that ... sockeye passed through extremely fast-moving water, we started to ... spawning grounds," said Nicholas Burnett, a research biologist at ...
(Date:8/20/2014)... 20, 2014 As concerns regarding the ... morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in gynecological surgery continue ... Senators from New York are urging the U.S. Food ... the devices. In a letter dated August 19th, Sens. ... the agency to seriously consider the testimony given during ...
(Date:8/20/2014)... NY (August 20, 2014) Research from Columbia University ... role in stomach cancer growth and that blocking nerve ... effective treatment for the disease. The study was conducted ... collaboration with Duan Chen, MD, PhD, in Norway and ... Medicine . , "Scientists have long observed that human ...
Breaking Medicine News(10 mins):Health News:Perkins Eastman Expands Presence in China 2Health News:Perkins Eastman Expands Presence in China 3Health News:New research shows seals and sea lions likely spread tuberculosis to humans 2Health News:New research shows seals and sea lions likely spread tuberculosis to humans 3Health News:Salmon forced to 'sprint' less likely to survive migration 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 4Health News:Severing nerves may shrink stomach cancers: Botox injections slow growth of tumors in mice 2
... with current devices , , MONDAY, Jan. 21 (HealthDay News) ... for overcoming the major problems with these tubes that ... Italian researchers report. , The new stent is not ... use, but with a special polymer designed to prevent ...
... in 2007, KNOXVILLE, Tenn., Jan. 21 ... clinical outsourcing, announced today,that it has initiated ... December 2007 and January 2008. These contracts ... medicine programs in seven,states., TeamHealth will ...
... WASHINGTON, Jan. 21 Senator Sam Brownback,and Rep. ... for Life, on,Tuesday, January 22, 2008. The conference ... College Professor Hadley P.,Arkes, Eric Scheidler, Michael Illions, ... live from Family Research Council,s headquarters., Senator ...
... DIEGO, Jan. 21 AMN Healthcare Services,Inc. (NYSE: ... United,States, will host its quarterly conference call to discuss ... 2008, at 5:00 p.m. Eastern,Time. The company expects to ... 2008 at approximately 4:00 p.m. Eastern Time., A ...
... Biosciences,(Nasdaq: MATK ) announced today that life,sDHA(TM), its ... heart health, is now available to,Australian consumers in Pocket ... is the largest juice and smoothie chain in the,Southern ... Pocket Rocket Juice provides,more than 100 percent of Australia,s ...
... kick butts, SAN DIEGO, Jan. 21 RealAge.com, ... a new program to guide and,support nicotine-free wannabes as ... Stop Smoking Center launched today. The center is packed,with ... MD, a,founder of RealAge and coauthor of YOU: Staying ...
Cached Medicine News:Health News:'Drug-Free' Stent Coating Shows Promise 2Health News:TeamHealth Announces Eight New Clinical Outsourcing Contracts 2Health News:Senator Sam Brownback and Rep. Chris Smith to Speak at Blogs for Life 2Health News:AMN Healthcare Services to Host 2007 Fourth Quarter & Year End Earnings Conference Call on Tuesday, February 26, 2008 2Health News:Pocket Rocket Juice from Australia's Boost Juice Features 700 mg of Martek's life'sDHA(TM) 2Health News:Pocket Rocket Juice from Australia's Boost Juice Features 700 mg of Martek's life'sDHA(TM) 3Health News:RealAge Challenges and Cheers Smoke-Free Wannabes in 2008 2
... enzyme linked immunosorbent assay ... and semiquantitation of anti-glomerular ... in human serum. The ... can be used as ...
An indirect immunofluorescence (IFA) antibody test for the detection and semiquantitation of anti-glomerular basement membrane (GBM) antibodies in human serum. Slide Detail: 6-well Monkey Kidney Subs...
Rheumatoid factor screening...
An enzyme linked immunosorbant assay (ELISA) for the detection and quantitation of Rheumatoid Factor (RF) IgA isotype in human serum....
Medicine Products: